Day 1: Tuesday, December 3, 2024

SESSION 1: Tackling emerging viruses

SESSION 2: Long-COVID

back to top

Day 2: Wednesday, December 4, 2024

SESSION 3: Barry-Wainberg DART Achievement Award Session

Session 4: Immunity and advances in vaccine development

SESSION 5: Industry Session

Novel ligand-targeted immunotherapy for the treatment of human respiratory syncytial virus

Jeffery Nielsen, Eradivir, USA

IM-250 – a 2nd generation, long-acting, nerve-tissue penetrating helicase primase inhibitor for the treatment of HSV infection and disease

Thomas Hoffman, Innovative Molecules, Germany

Immunogenicity and protective efficacy of respiratory syncytial virus mRNA vaccine encoding the F protein of both RSV subtypes A and B in a BALB/c mouse model

Sujin Lee, Vernagen, Emory University, USA

Virologic response and safety after oral administration of PF-07817883, a novel SARS-CoV-2 Mpro inhibitor, in nonhospitalized adults with symptomatic COVID-19

Mahta Mortezavi, Pfizer, USA

Discovery and Preclinical Profile of ALG-097558, a SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19

David McGowan, Aligos Therapeutics, USA

SESSION 6:  Immune responses and emerging viruses

Oral Abstract Session I

Discovery of broad-spectrum antivirals targeting viral proteases using in silico structural modeling and analysis

Dharmeshkumar Patel, Emory University, USA

The rapid evolution of the 2022-23 monkeypox outbreak: An investigation of APOBEC3-derived mutations

Rachel Liu, SUNY Binghamton University, USA

Elicitation of potent antibody responses against highly pathogenic avian influenza subtypes H5N1 and H7N9 by sequential vaccination of Indian rhesus macaques with hemagglutinin-encoding mRNA-LNPs and recombinant adenovirus type 5 vectors

Brandon Rosen, George Washington University, USA

Exhaustive characterization of the broad-spectrum activity of flavivirus protease inhibitors

Dario Akaberi, Uppsala University, Sweden

back to top

Day 3: Thursday, December 5, 2024

SESSION 7: Immuological and antiviral protease approaches to Coronavirus infections

Oral Abstract Session II

Systems immunology defines immunological profiles associated with Long COVID onset and recovery

Andrea Cox, Johns Hopkins University, USA

Mechanistic Insights on Small Molecule Entry Inhibitors of Influenza A Viruses

Lijun Rong, University of Illinois, USA

Summary of Posters and Meeting

Boghuma Kabisen Titanji, Emory University, USA

Oral Abstract Session 3 (non-CME)

A small molecule based bispecific antigenic immunotherapy for the treatment of dengue

Conrrad Nicholls, Eradivir, USA

Safety, pharmacokinetics, and drug-drug interaction potential of single and multiple ascending doses of ALG-097558, a pan-coronavirus 3CL protease inhibitor, and relative bioavailability/food effect of a solid formulation in healthy volunteers

Stanley Wang, Aligos Therapeutics, USA

Integrated clinical virologic analysis across EPIC clinical trials reveals resistance to Nirmatrelvir/Ritonavir is rare

Mary Lynn Baniecki, Pfizer, USA

Business of antiviral agents

Frank Rahmani

Name, Affiliation